Welcome to our dedicated page for PHAXIAM THERAPEUTICS S A news (Ticker: PHXM), a resource for investors and traders seeking the latest updates and insights on PHAXIAM THERAPEUTICS S A stock.
PHAXIAM Therapeutics S A (PHXM) delivers innovative therapies for oncology and orphan diseases through its proprietary red blood cell encapsulation technology. This dedicated news hub provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic partnerships.
Access official press releases and verified updates about PHXM's pioneering research in tumor-related conditions and rare diseases. Our curated collection includes announcements about trial progress, manufacturing advancements from their Lyon facility, and collaborations enhancing therapeutic distribution.
Key updates cover drug encapsulation innovations, patient trial recruitment statuses, and European regulatory engagements. Bookmark this page for consolidated access to PHXM's latest scientific advancements and operational developments, presented with clarity for both expert analysts and engaged stakeholders.
PHAXIAM Therapeutics (Euronext: PHXM) announced the results of its Combined General Meeting held on June 28, 2024. Shareholders approved all recommended resolutions, including the annual financial statements for the year ending December 31, 2023, allocation of the year's results, and the remuneration policy for executives. Key approvals included the stock option plan, the appointment of Valérie Faillat as Director, and the delegation of powers to issue shares or convertible securities. Additionally, the Board received authorization to grant free shares, share options, and share warrants to company officers and employees. Full documentation and detailed results are available on the company's website.
PHAXIAM Therapeutics (Euronext: PHXM), a company focused on developing treatments for severe and resistant bacterial infections, has released preparatory documents for its Combined General Meeting scheduled for 28 June 2024. The meeting will take place at 9:30 a.m. at the company's registered office in Lyon, France. Shareholders can attend in person, vote remotely via post or the Votaccess platform, or assign a proxy to vote on their behalf. The documents, including the agenda and draft resolutions, are available on PHAXIAM's website. Shareholders are encouraged to check the site regularly for updates.
As of May 31, 2024, PHXM reported no change in the total number of shares composing its share capital, remaining at 6,075,105 shares.
The total gross voting rights are 6,226,989, while the net voting rights stand at 6,226,740. These figures indicate slight fluctuations over the past five months, with minor variations in both gross and net voting rights.
PHXM's shares are listed on the Euronext Paris market under the ISIN Code FR001400K4B1.
PHAXIAM Therapeutics, a biopharmaceutical firm specializing in phage therapy for bacterial infections, has released its Q1 2024 business and financial update. The company is advancing its Staphylococcus aureus programs, including a global Phase 2 study for Prosthetic Joint Infections (PJI) and a Phase 1 study for Endocarditis Infections (EI). Upcoming milestones include preliminary PK data (3Q 2024) and the launch of the global Phase 2 PJI study (1Q 2025). As of March 31, 2024, PHAXIAM held €5.8 million in cash, sufficient to fund operations until August 2024. Efforts are underway to secure additional financing.
PHXM releases monthly information on the total number of voting rights and shares composing the share capital for April 30, 2024. The data shows consistency in the number of shares and voting rights over the past few months, with 6,075,105 shares and 6,226,932 gross and net voting rights, respectively.
